Evidence map›Paper›PMID 40496449›Full record

ArticleFrontiers in public health2025

Making human papillomavirus testing a public health priority in Ecuador.

Gustavo Galárraga, José Francisco López-Gil

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gustavo GalárragaSchool of Public Health, University of Minnesota, Minneapolis, MN, United States.
José Francisco López-GilOne Health Research Group, Universidad de Las Américas, Quito, Ecuador.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is a pressing public health issue in Ecuador, where it is the second most common cancer among women, with 1792 new cases and 939 deaths annually. Despite the availability of superior diagnostic methods like human papillomavirus deoxyribonucleic acid testing, the national strategy continues to prioritize Pap smears, limiting the effectiveness of early detection efforts. Disparities in screening access are evident, with only 54% of women aged 12-49 undergoing Pap smears, and coverage is even lower in marginalized populations. Learning from Peru's National Cancer Law, Ecuador has the opportunity to adopt similar measures, ensuring free and equitable access to human papillomavirus (HPV) testing. By scaling up human papillomavirus screening, integrating vaccination programs, and addressing socioeconomic barriers, Ecuador can move closer to eliminating cervical cancer as a public health threat. The time to prioritize human papillomavirus testing is now.

Indexed as

Health PrioritiesMass ScreeningPapillomavirus InfectionsPublic HealthUterine Cervical NeoplasmsAdolescentAdultChildEarly Detection of CancerEcuadorFemaleHealth Services AccessibilityHuman Papillomavirus VirusesHumansMiddle AgedPapanicolaou TestPapillomavirus Vaccinescervical cancerhealth disparitieshealth equitypap smearpublic healthscreening policiesvaccination programs

Identifiers

PMID40496449
PMCPMC12149154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.